Improving quality of life with nabilone during radiotherapy treatments for head and neck cancers: A randomized double-blind placebo-controlled trial

Annals of Otology, Rhinology and Laryngology

Volumn 125, Issue 4, 2016, Pages 317-324

  Côté, Mathieu ^a,b   Trudel, Mathieu ^a,b   Wang, Changshu ^c   Fortin, André ^a,b  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c CENTRE HOSPITALIER UNIVERSITAIRE DE SHERBROOKE   (Canada)

Author keywords

Cannabinoid; Head and neck cancer; Nabilone; Quality of life; Radiotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; CODEINE; FENTANYL; HYDROMORPHONE; METOCLOPRAMIDE; NABILONE; PARACETAMOL; PLACEBO; ANTIEMETIC AGENT; DRONABINOL;

ADULT; ANXIETY DISORDER; APPETITE; ARTICLE; BEDTIME DOSAGE; BODY WEIGHT DISORDER; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER RADIOTHERAPY; CANCER SURGERY; CHEMORADIOTHERAPY; CONTROLLED STUDY; DETERIORATION; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG DOSE INCREASE; DRUG EFFICACY; FEMALE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HEAD AND NECK SURGERY; HUMAN; LOSS OF APPETITE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOOD DISORDER; MULTIMODALITY CANCER THERAPY; PAIN ASSESSMENT; POSTOPERATIVE CARE; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RADIATION INJURY; RADIATION PNEUMONIA; RADIATION SICKNESS; RANDOMIZED CONTROLLED TRIAL; SLEEP DISORDER; UNSPECIFIED SIDE EFFECT; VISUAL ANALOG SCALE; XEROSTOMIA; AFFECT; ANALOGS AND DERIVATIVES; BODY WEIGHT; CARCINOMA, SQUAMOUS CELL; HEAD AND NECK NEOPLASMS; NAUSEA; PAIN; PAIN MEASUREMENT; RADIOTHERAPY; SLEEP;

AFFECT; ANTIEMETICS; APPETITE; BODY WEIGHT; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DOUBLE-BLIND METHOD; DRONABINOL; FEMALE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NAUSEA; PAIN; PAIN MEASUREMENT; QUALITY OF LIFE; RADIOTHERAPY; SLEEP;

EID: 84964010173     PISSN: 00034894     EISSN: None     Source Type: Journal    
DOI: 10.1177/0003489415612801     Document Type: Article

References (37)

1. Fitzmaurice C, Dicker D, Pain A, et al. The global burden of cancer 2013. JAMA Oncol. 2015;1:505-527.
2. Wolf GT, Hong WK, Fischer SG, et al. Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med. 1991;324:1685-1690.
3. Weber RS, Berkey BA, Forastiere A, et al. Outcome of salvage total laryngectomy following organ preservation therapy: the Radiation Therapy Oncology Group trial 91-11. Arch Otolaryngol Head Neck Surg. 2003;129:44-49.
4. Brizel DM, Albers ME, Fisher SR, et al. Hyperfractionated irradiation with or without concurrent chemotherapy for locally advanced head and neck cancer. N Engl J Med. 1998;338:1798-1804.
5. Denis F, Garaud P, Bardet E, et al. Final results of the 94-01 French Head and Neck Oncology and Radiotherapy Group randomized trial comparing radiotherapy alone with concomitant radiochemotherapy in advanced-stage oropharynx carcinoma. J Clin Oncol. 2004;22:69-76.
6. Pignon JP, le Maitre A, Maillard E, Bourhis J. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol. 2009;92:4-14.
7. Moon SH, Cho KH, Chung EJ, et al. A prospective randomized trial comparing hypofractionation with conventional fractionation radiotherapy for T1-2 glottic squamous cell carcinomas: results of a Korean Radiation Oncology Group (KROG-0201) study. Radiother Oncol. 2014;110:98-103.
8. Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck. N Engl J Med. 2004;350:1937-1944.
9. Bernier J, Domenge C, Ozsahin M, et al. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med. 2004;350:1945-1952.
10. Furness S, Glenny AM, Worthington HV, et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: chemotherapy. Cochrane Database Syst Rev. 2011:CD006386.
11. Glenny AM, Furness S, Worthington HV, et al. Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy. Cochrane Database Syst Rev. 2010:CD006387.
12. Nguyen-Tan PF, Zhang Q, Ang KK, et al. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol. 2014;32:3858-3866.
13. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
14. Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. J Clin Oncol. 2014;32:2940-2950.
15. Trotti A, Pajak TF, Gwede CK, et al. TAME: development of a new method for summarising adverse events of cancer treatment by the Radiation Therapy Oncology Group. Lancet Oncol. 2007;8:613-624.
16. Givens DJ, Karnell LH, Gupta AK, et al. Adverse events associated with concurrent chemoradiation therapy in patients with head and neck cancer. Arch Otol Head Neck Surg. 2009;135:1209-1217.
17. Verdonck-de Leeuw IM, Buffart LM, Heymans MW, et al. The course of health-related quality of life in head and neck cancer patients treated with chemoradiation: a prospective cohort study. Radiother Oncol. 2014;110:422-8.
18. Eades M, Murphy J, Carney S, et al. Effect of an interdisciplinary rehabilitation program on quality of life in patients with head and neck cancer: review of clinical experience. Head Neck. 2013;35:343-349.
19. Klein J, Livergant J, Ringash J. Health related quality of life in head and neck cancer treated with radiation therapy with or without chemotherapy: a systematic review. Oral Oncol. 2014;50:254-262.
20. So WK, Choi KC, Chen JM, et al. Quality of life in head and neck cancer survivors at 1 year after treatment: the mediating role of unmet supportive care needs. Support Care Cancer. 2014;22:2917-2926.
21. Sallan SE, Cronin C, Zelen M, Zinberg NE. Antiemetics in patients receiving chemotherapy for cancer: a randomized comparison of delta-9-tetrahydrocannabinol and prochlorperazine. N Engl J Med. 1980;302:135-138.
22. Meiri E, Jhangiani H, Vredenburgh JJ, et al. Efficacy of dronabinol alone and in combination with ondansetron versus ondansetron alone for delayed chemotherapy-induced nausea and vomiting. Curr Med Res Opin. 2007;23:533-543.
23. Beal JE, Olson R, Laubenstein L, et al. Dronabinol as a treatment for anorexia associated with weight loss in patients with AIDS. J Pain Symptom Manage. 1995;10:89-97.
24. Walsh D, Nelson KA, Mahmoud FA. Established and potential therapeutic applications of cannabinoids in oncology. Support Care Cancer. 2003;11:137-143.
25. Guzman M. Cannabinoids: potential anticancer agents. Nat Rev Cancer. 2003;3:745-755.
26. King MT. The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res. 1996;5:555-567.
27. Osoba D, Rodrigues G, Myles J, Zee B, Pater J. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol. 1998;16:139-144.
28. Bijur PE, Silver W, Gallagher EJ. Reliability of the visual analog scale for measurement of acute pain. Acad Emerg Med. 2001;8:1153-1157.
29. Fayers P, Weeden S, Curran D. EORTC QLQ-C30 Reference Values: EORTC Monograph; 1998.
30. Wesnes KA, Annas P, Edgar CJ, et al. Nabilone produces marked impairments to cognitive function and changes in subjective state in healthy volunteers. J Psychopharmacol. 2010;24:1659-1669.
31. Enblom A, Bergius Axelsson B, Steineck G, Hammar M, Borjeson S. One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient. Support Care Cancer. 2009;17:23-32.
32. Schwartzberg LS. Chemotherapy-induced nausea and vomiting: clinician and patient perspectives. J Support Oncol. 2007;5:5-12.
33. Machado Rocha FC, Stefano SC, De Cassia Haiek R, Rosa Oliveira LM, Da Silveira DX. Therapeutic use of cannabis sativa on chemotherapy-induced nausea and vomiting among cancer patients: systematic review and meta-analysis. Eur J Cancer Care. 2008;17:431-443.
34. Rao AS, Camilleri M. Review article: metoclopramide and tardive dyskinesia. Aliment Pharmacol Ther. 2010;31: 11-19.
35. Maida V, Ennis M, Irani S, Corbo M, Dolzhykov M. Adjunctive nabilone in cancer pain and symptom management: a prospective observational study using propensity scoring. J Support Oncol. 2008;6:119-124.
36. Davis MP. Oral nabilone capsules in the treatment of chemotherapy-induced nausea and vomiting and pain. Expert Opin Investig Drugs. 2008;17:85-95.
37. Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. BMJ. 2001;323:16-21.